Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|June 11, 2026 (Updated: June 10, 2026)

The BioPharm Brief: CAR-T Progress, ADC Momentum, Biosimilar Expansion

New developments in CAR-T cell therapy, antibody-drug conjugates, and biosimilars highlight continued innovation across oncology and immunology.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today we're looking at three stories that highlight advances in cell therapy, targeted oncology treatments, and biosimilar medicines.

First, Imviva Biotech reported encouraging data for its investigational allogeneic CAR-T therapy CTD402 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma. Data presented at the European Hematology Association Congress showed an overall response rate of nearly 86% in adults and an 80% complete remission rate in pediatric patients. The findings add to growing interest in off-the-shelf CAR-T therapies, which could help eliminate manufacturing delays associated with patient-specific treatments.

In antibody-drug conjugate news, Immunome announced that the first patient has been dosed in a Phase 1 trial evaluating IM-1617, a potential first-in-class ADC for advanced solid tumors. The investigational therapy combines a tumor-targeting antibody with the company's proprietary topoisomerase I inhibitor payload and is being evaluated in patients with colorectal cancer, non-small cell lung cancer, breast cancer, and other advanced solid tumors. The milestone marks another step forward in the rapidly expanding ADC field.

Finally, the FDA expanded the label of a tocilizumab biosimilar to include cytokine release syndrome and pediatric COVID-19 indications. The approval broadens patient access to an important immunology therapy while underscoring the growing role biosimilars continue to play in reducing treatment costs and expanding healthcare access.

Taken together, today's stories reflect three major themes shaping biopharma: increasing momentum for off-the-shelf cell therapies, continued investment in next-generation targeted oncology platforms, and expanding regulatory support for biosimilar adoption.

That's all for today's BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • Imviva reported strong response rates for its allogeneic CAR-T therapy CTD402 in relapsed or refractory T-ALL/LBL.
  • Immunome dosed the first patient in a Phase 1 trial of its potential first-in-class ADC IM-1617.
  • The FDA expanded indications for a tocilizumab biosimilar, increasing patient access to treatment.

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.